Video

AsclepiX lead candidate holds potential for wet AMD, DME, RVO (ASRS 2020)

Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis.


Theresa Heah, MD, provides an update on AsclepiX’s AXT107, which is derived from a cryptic peptide within collagen IV that works by activating naturally existing, homeostatic mechanisms of angiogenesis, during the virtual 2020 American Society of Retina Specialists (ASRS) annual meeting.

See more ASRS meeting coverage here

Related Videos
Image credit: Ophthalmology Times; Angiogenesis 2025: Encapsulated cell therapy for MacTel shows long-term efficacy in phase 3 trials
Lana Rifkin, MD, uveitis committee chair at EnVision Summit 2025
© 2025 MJH Life Sciences

All rights reserved.